Appleby advises Consun Pharmaceutical Group on Hong Kong Stock Exchange listing

Appleby has acted as Cayman counsel for Consun Pharmaceutical Group in relation to its listing on the Main Board of the Hong Kong Stock Exchange on 19 December 2013, with net proceeds of approximately HK$897.5m (£70m).

Consun will use the majority of the proceeds from the offering for infrastructure investment as well as research and development activities for new product development. The remaining proceeds will be used for the expansion of existing marketing and distribution networks, mergers and acquisitions and working capital and other general corporate purposes.

The Appleby team was led by Judy Lee, a corporate partner in Appleby’s Hong Kong office, assisted by associate Jo Lit.

Li & Partners advised the company as to Hong Kong law and Jingtian & Gongcheng advised the company as to PRC law, while Eversheds and Jia Yuan Law Offices advised the underwriters as to Hong Kong law and PRC law respectively.

BOCI Asia is the sole sponsor and underwriter for the IPO.

This information was originally sourced from the Appleby website.

  • Print

Briefings from Appleby

View more briefings from Appleby

Analysis from The Lawyer

View more analysis from The Lawyer


1st Floor
3 Copthall Avenue

Total staff: 528
Partners: 64